Searchable abstracts of presentations at key conferences in endocrinology

ea0092ps3-24-05 | Thyroid Eye Disease | ETA2023

Teprotumumab for the treatment of recalcitrant thyroid eye disease

Men Clara , Amarikwa Linus , Sears Connie , Shinder Roman , Clauss Kevin , Ugradar Shoaib , Cockerham Kimberly , Wester Sara , Douglas Raymond , Kossler Andrea

Introduction: The initial clinical trials for teprotumumab excluded patients with previous orbital irradiation, surgery, glucocorticoid use (cumulative dose > 1gm), or biologic treatment. Therefore, information on the use of teprotumumab for patients who failed prior therapy is limited. Our purpose is to characterize the efficacy of teprotumumab for the treatment of recalcitrant TED.Methods: This is a multicenter retrospective study of all patients t...

ea0092op-04-02 | Oral Session 4: Young Investigators / Clinical and Translational | ETA2023

Teprotumumab-Related adverse events in thyroid eye disease: a multi-center real world study

Shah Shreya , Amarikwa Linus , Sears Connie , Ugradar Shoaib , Clauss Kevin , Rajjoub Raneem , Kang Julia , Tamhankar Madhura , Briceno Cesar , Harrison Andrew , Dosiou Chrysoula , Cockerham Kimberly , Wester Sara , Douglas Raymond , Kossler Andrea

Objectives: The insulin-like growth factor I receptor (IGF-1R) plays a significant role in the pathology of thyroid eye disease (TED), an autoimmune disorder characterized by orbital inflammation. Teprotumumab, a human monoclonal antibody targeting IGF-1R, has demonstrated efficacy in treating moderate-to-severe TED. A significant proportion of patients experienced adverse events (AEs), with 74% and 85% reporting an AE and 12% and 5% reporting serious AEs in Phase 2 and 3 tria...